Listas de seguimiento Ideas ProPicks IA Filtro Explorador de datos Gráficos Trabajo guardado

SAGE Therapeutics Inc

NASDAQGM:SAGE

Estados Unidos / Salud / Biotecnología

Visión general

Finanzas históricas a 5 años

Precio

8,53 USD


Key Metrics	Latest
Total Revenue	41,243 M
Adjusted EBITDA	-409,5 M
EBITDA Margin	-992,9%
Net Profit Margin	-932,3%
Total Assets	547,2 M
Total Debt	11,836 M

5Y Historical Financial Statements

Summary Financials


Summary Financials

	Fiscal Year Ending					Latest	Year-to-date Ending
(in millions)	Dec-20	Dec-21	Dec-22	Dec-23	Dec-24	12 Months	Dec-23	Dec-24

Revenue	1,114.20	6.31	7.69	86.46	41.24	41.24	86.46	41.24
% Growth		(0.99)	0.22	10.25	(0.52)			(0.52)

Adjusted EBITDA	626.60	(456.73)	(545.87)	(545.07)	(409.49)	(409.49)	(545.07)	(409.49)
% Margin	0.56	(72.40)	(71.02)	(6.30)	(9.93)	(9.93)	(6.30)	(9.93)

Adjusted EBIT	623.97	(460.91)	(546.99)	(546.46)	(410.52)	(410.52)	(546.46)	(410.52)
% Margin	0.56	(73.07)	(71.17)	(6.32)	(9.95)	(9.95)	(6.32)	(9.95)

Adjusted Net Income	626.60	(457.89)	(532.78)	(516.78)	(384.49)	(384.49)	(516.78)	(384.49)
% Margin	0.56	(72.59)	(69.32)	(5.98)	(9.32)	(9.32)	(5.98)	(9.32)

Adjusted Basic EPS	12.05	(7.80)	(8.98)	(8.64)	(6.33)	(6.33)	(8.64)	(6.33)

Cálculos de apoyo

Income Statement

Balance Sheet

Statement of Cashflows


Income Statement
						Original
USD	Fiscal Year Ending					Latest	Year-to-date Ending
(in millions)	Dec-20	Dec-21	Dec-22	Dec-23	Dec-24	Dec-24	Dec-23	Dec-24
	FY - 4	FY - 3	FY - 2	FY - 1	FY	LTM	YTD-1	YTD

Revenue	1,114	6	8	86	41	41	86	41
% Growth	NA	-99.4%	21.8%	1024.8%	-52.3%			-52.3%

Cost of Revenue	(293)	(284)	(327)	(358)	(235)	(235)	(358)	(235)
Gross Profit	821	(277)	(319)	(272)	(194)	(194)	(272)	(194)
% Revenue	73.7%	-4397.8%	-4154.2%	-314.5%	-470.6%	-470.6%	-314.5%	-470.6%

Research and Development	(293)	(363)	(326)	(432)	(242)	(242)	(432)	(242)
Selling and Marketing	0	0	0	0	0	0	0	0
General and Admin	(197)	(183)	(228)	(275)	(216)	(216)	(275)	(216)
Other Inc / (Exp)	265	363	326	399	220	220	399	220
Total Operating Exp	(224)	(183)	(228)	(308)	(238)	(238)	(308)	(238)

Operating Income	596	(461)	(547)	(580)	(432)	(432)	(580)	(432)
% Revenue	53.5%	-7304.6%	-7116.5%	-671.1%	-1048.3%	-1048.3%	-671.1%	-1048.3%

Interest Expense	10	3	14	39	32	32	39	32
Pre-tax Income	606	(458)	(533)	(541)	(401)	(401)	(541)	(401)
Earnings of Discontinued Ops.	0	0	0	0	0	0	0	0
Provision for Taxes	0	0	0	0	0	0	0	0
Net Income to Company	606	(458)	(533)	(541)	(401)	(401)	(541)	(401)
% Margin	54.4%	-7258.9%	-6931.9%	-626.3%	-971.5%	-971.5%	-626.3%	-971.5%

Minority Interest in Earnings	0	0	0	0	0	0	0	0
Net Income to Stockholders	606	(458)	(533)	(541)	(401)	(401)	(541)	(401)

Preferred Dividends	0	0	0	0	0	0	0	0
Other Adj.	0	0	0	0	0	0	0	0

Net Income to Common	606	(458)	(533)	(541)	(401)	(401)	(541)	(401)
% Margin	54.4%	-7258.9%	-6931.9%	-626.3%	-971.5%	-971.5%	-626.3%	-971.5%

As Reported
Basic EPS (Continuing Ops)	11.66	(7.80)	(8.98)	(9.05)	(6.59)	(6.59)	(9.05)	(6.59)
Diluted EPS (Continuing Ops)	11.43	(7.80)	(8.98)	(9.05)	(6.59)	(6.59)	(9.05)	(6.59)

WA Basic Shares Out.	51.98	58.67	59.31	59.84	60.77	60.77	59.84	60.77
WA Diluted Shares Out.	53.00	58.67	59.31	59.84	60.77	60.77	59.84	60.77

EBITDA, EBIT Reconciliation
EBT, Incl. Unusual Items	606	(458)	(533)	(541)	(401)	(401)	(541)	(401)
Addback: Net Interest Expense	(10)	(3)	(14)	(39)	(32)	(32)	(39)	(32)
Addback: Other Non Operating Expenses, Total	(0)	(0)	(0)	0	(0)	(0)	0	(0)
Addback: Depreciation & Amortization	3	4	1	1	1	1	1	1
Addback: Restructuring Charges	28	0	0	33	22	22	33	22
Addback: Merger / Acquisition Expenses	0	0	0	0	0	0	0	0
Addback: Goodwill Impairment	0	0	0	0	0	0	0	0
Addback: Gain (Loss) On Sale Of Invest.	0	0	0	0	0	0	0	0
Addback: Gain (Loss) On Sale Of Assets	0	0	0	0	0	0	0	0
Addback: Asset Writedown	0	0	0	0	0	0	0	0
Addback: In Process R&D Expenses	0	0	0	0	0	0	0	0
Addback: Insurance Settlements	0	0	0	0	0	0	0	0
Addback: Legal Settlements	0	0	0	0	0	0	0	0
Addback: Other Unusual Items	0	0	0	0	0	0	0	0
Adjusted EBITDA	627	(457)	(546)	(545)	(409)	(409)	(545)	(409)
% Margin	56.2%	-7240.4%	-7102.1%	-630.5%	-992.9%	-992.9%	-630.5%	-992.9%

Adjusted EBIT	624	(461)	(547)	(546)	(411)	(411)	(546)	(411)
% Margin	56.0%	-7306.7%	-7116.7%	-632.1%	-995.4%	-995.4%	-632.1%	-995.4%

Adjusted Net Income Reconciliation
Net Income to Company	606	(458)	(533)	(541)	(401)	(401)	(541)	(401)
Addback: Unusual Items	28	0	0	33	22	22	33	22
Less: Tax Benefit of Unusual Items (26%)	(7)	0	0	(9)	(6)	(6)	(9)	(6)
Adjusted Net Income	627	(458)	(533)	(517)	(384)	(384)	(517)	(384)
% Margin	56.2%	-7258.9%	-6931.9%	-597.7%	-932.3%	-932.3%	-597.7%	-932.3%

Error de carga

SAGE Therapeutics Inc

NASDAQGM:SAGE

Estados Unidos / Salud / Biotecnología

Finanzas históricas a 5 años